Poly(ADP-ribose) polymerase1 (PARP1) and PARP inhibitors: New frontiers in cervical cancer.

Autor: Rajawat J; Institute of Advanced Molecular Genetics & Infectious Diseases, ONGC-CAS, University of Lucknow, Lucknow, 226007, U.P, India; Molecular & Human Genetics Lab, Department of Zoology, University of Lucknow, Lucknow, 226007, U.P, India. Electronic address: jrajawat@gmail.com., Banerjee M; Molecular & Human Genetics Lab, Department of Zoology, University of Lucknow, Lucknow, 226007, U.P, India; A Laboratory of Advanced Molecular Genetics & Infectious Diseases, ONGC-CAS, University of Lucknow, Lucknow, 226007, U.P, India. Electronic address: monishabanerjee30@gmail.com.

Publikováno v: Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2024 Dec 17; Vol. 738, pp. 150943. Date of Electronic Publication: 2024 Nov 02.

The recent advance and prospect of poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.

Autor: Bai YR; Department of Pharmacy, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, China.; Key Laboratory of Advanced Drug Preparation Technologies, School of Pharmacy, Zhengzhou University, Zhengzhou, China., Yang WG; Department of Pharmacy, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, China., Jia R; Department of Pharmacy, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, China., Sun JS; Department of Pharmacy, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, China., Shen DD; Department of Obstetrics and Gynecology, Zhengzhou Key Laboratory of Endometrial Disease Prevention and Treatment, Zhengzhou, China.; Gynecology Department, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China., Liu HM; Department of Pharmacy, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, China.; Key Laboratory of Advanced Drug Preparation Technologies, School of Pharmacy, Zhengzhou University, Zhengzhou, China., Yuan S; Department of Pharmacy, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, China.; Key Laboratory of Advanced Drug Preparation Technologies, School of Pharmacy, Zhengzhou University, Zhengzhou, China.

Publikováno v: Medicinal research reviews [Med Res Rev] 2025 Jan; Vol. 45 (1), pp. 214-273. Date of Electronic Publication: 2024 Aug 24.

Regorafenib induces DNA damage and enhances PARP inhibitor efficacy in pancreatic ductal carcinoma.

Autor: Pham TD; Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. thao.pham@northwestern.edu.; The Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA. thao.pham@northwestern.edu., Becker JH; Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.; Jesse Brown VA Medical Center, Chicago, IL, USA., Metropulos AE; Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.; Jesse Brown VA Medical Center, Chicago, IL, USA., Mubin N; Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.; Jesse Brown VA Medical Center, Chicago, IL, USA., Spaulding C; Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA., Bentrem DJ; Jesse Brown VA Medical Center, Chicago, IL, USA.; The Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA.; Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA., Munshi HG; Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. h-munshi@northwestern.edu.; Jesse Brown VA Medical Center, Chicago, IL, USA. h-munshi@northwestern.edu.; The Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA. h-munshi@northwestern.edu.

Publikováno v: BMC cancer [BMC Cancer] 2024 Dec 20; Vol. 24 (1), pp. 1562. Date of Electronic Publication: 2024 Dec 20.

Elucidating acquired PARP inhibitor resistance in advanced prostate cancer.

Autor: Seed G; The Institute of Cancer Research, London, UK., Beije N; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK., Yuan W; The Institute of Cancer Research, London, UK., Bertan C; The Institute of Cancer Research, London, UK., Goodall J; The Institute of Cancer Research, London, UK., Lundberg A; The Institute of Cancer Research, London, UK., Tyler M; The Institute of Cancer Research, London, UK., Figueiredo I; The Institute of Cancer Research, London, UK., Pereira R; The Institute of Cancer Research, London, UK., Baker C; The Institute of Cancer Research, London, UK., Bogdan D; The Institute of Cancer Research, London, UK., Gallagher L; The Institute of Cancer Research, London, UK., Cieslik JP; Heinrich Heine University, Düsseldorf, Germany., Greening S; The Institute of Cancer Research, London, UK., Lambros M; The Institute of Cancer Research, London, UK., Neves R; Heinrich Heine University, Düsseldorf, Germany., Magraner-Pardo L; The Institute of Cancer Research, London, UK., Fowler G; The Institute of Cancer Research, London, UK., Ebbs B; The Institute of Cancer Research, London, UK., Miranda S; The Institute of Cancer Research, London, UK., Flohr P; The Institute of Cancer Research, London, UK., Bianchini D; The Royal Marsden NHS Foundation Trust, London, UK., Rescigno P; The Institute of Cancer Research, London, UK., Porta N; The Institute of Cancer Research, London, UK., Hall E; The Institute of Cancer Research, London, UK., Gurel B; The Institute of Cancer Research, London, UK., Tunariu N; The Royal Marsden NHS Foundation Trust, London, UK., Sharp A; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK., Pettit S; The Institute of Cancer Research, London, UK., Stoecklein NH; Heinrich Heine University, Düsseldorf, Germany., Sandhu S; The Royal Marsden NHS Foundation Trust, London, UK., Quigley D; UCSF, San Francisco, CA, USA., Lord CJ; The Institute of Cancer Research, London, UK., Mateo J; Vall d'Hebron Institute of Oncology, Barcelona, Spain., Carreira S; The Institute of Cancer Research, London, UK., de Bono J; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: johann.de-bono@icr.ac.uk.

Publikováno v: Cancer cell [Cancer Cell] 2024 Dec 09; Vol. 42 (12), pp. 2113-2123.e4. Date of Electronic Publication: 2024 Nov 21.

Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors.

Autor: Chou J; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, California., Robinson TM; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.; Department of Radiation Oncology, University of California San Francisco, San Francisco, California., Egusa EA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.; Department of Radiation Oncology, University of California San Francisco, San Francisco, California., Lodha R; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.; Department of Radiation Oncology, University of California San Francisco, San Francisco, California., Zhang M; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.; Department of Radiation Oncology, University of California San Francisco, San Francisco, California., Badura M; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.; Department of Radiation Oncology, University of California San Francisco, San Francisco, California., Mikayelyan M; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.; Department of Radiation Oncology, University of California San Francisco, San Francisco, California., Delavan HM; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, California., Swinderman J; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.; Department of Radiation Oncology, University of California San Francisco, San Francisco, California., Wilson C; Department of Pharmaceutical Chemistry and the Small Molecule Discovery Center, University of California San Francisco, San Francisco, California., Zhu J; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.; Department of Radiation Oncology, University of California San Francisco, San Francisco, California., Das R; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.; Department of Radiation Oncology, University of California San Francisco, San Francisco, California., Nguyen M; Clovis Oncology, Inc., Boulder, Colorado., Loehr A; Clovis Oncology, Inc., Boulder, Colorado., Golsorkhi T; Clovis Oncology, Inc., Boulder, Colorado., Simmons A; Clovis Oncology, Inc., Boulder, Colorado., Abida W; Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York., Chinnaiyan AM; Department of Pathology, University of Michigan, Ann Arbor, Michigan.; Howard Hughes Medical Institute, University of Michigan, Ann Arbor, Michigan., Arkin MR; Department of Pharmaceutical Chemistry and the Small Molecule Discovery Center, University of California San Francisco, San Francisco, California., Small EJ; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, California., Quigley DA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.; Department of Urology, University of California San Francisco, San Francisco, California.; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California., Yang L; Ben May Department for Cancer Research, University of Chicago, Chicago, Illinois.; Department of Human Genetics, University of Chicago, Chicago, Illinois., Kim M; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.; Department of Cellular Molecular Pharmacology, University of California San Francisco, San Francisco, California.; Department of Biochemistry and Structural Biology, University of Texas Health Science Center, San Antonio, Texas., Ashworth A; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, California., Feng FY; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.; Department of Radiation Oncology, University of California San Francisco, San Francisco, California.; Department of Urology, University of California San Francisco, San Francisco, California.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Dec 02; Vol. 30 (23), pp. 5445-5458.